Karyopharm Therapeutics Inc. [NASDAQ: KPTI] slipped around -1.89 points on Thursday, while shares priced at $5.93 at the close of the session, down -24.17%. The company report on August 5, 2021 that Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results.
— Achieved Second Quarter 2021 XPOVIO® (selinexor) Net Product Revenues of $20.2 Million and $41.9 Million YTD, Up 8% Versus Second Quarter 2020 and Up 21% Versus First Half of 2020 –.
— Looking Forward to a Milestone-Driven Second Half of 2021, Including Top-Line Data from Phase 3 SIENDO Study in Endometrial Cancer and Initiations and Expansions of Key Clinical Trials in Myelodysplastic Syndrome, Myelofibrosis, Multiple Myeloma & Colorectal Cancer –.
Karyopharm Therapeutics Inc. stock is now -61.69% down from its year-to-date (YTD) trading value. KPTI Stock saw the intraday high of $6.45 and lowest of $5.76 per share. The company’s 52-week high price is 18.00, which means current price is +2.95% above from all time high which was touched on 01/05/21.
Compared to the average trading volume of 1.37M shares, KPTI reached a trading volume of 6863317 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Karyopharm Therapeutics Inc. [KPTI]?
Morgan Stanley have made an estimate for Karyopharm Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 02, 2020. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on March 04, 2020, representing the official price target for Karyopharm Therapeutics Inc. stock. On July 23, 2019, analysts increased their price target for KPTI shares from 8 to 16.
The Average True Range (ATR) for Karyopharm Therapeutics Inc. is set at 0.53, with the Price to Sales ratio for KPTI stock in the period of the last 12 months amounting to 3.95.
How has KPTI stock performed recently?
Karyopharm Therapeutics Inc. [KPTI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -29.15. With this latest performance, KPTI shares dropped by -41.11% in over the last four-week period, additionally sinking by -59.38% over the last 6 months – not to mention a drop of -62.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KPTI stock in for the last two-week period is set at 18.66, with the RSI for the last a single of trading hit 13.01, and the three-weeks RSI is set at 23.86 for Karyopharm Therapeutics Inc. [KPTI]. The present Moving Average for the last 50 days of trading for this stock 9.52, while it was recorded at 7.65 for the last single week of trading, and 12.43 for the last 200 days.
Karyopharm Therapeutics Inc. [KPTI]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Karyopharm Therapeutics Inc. [KPTI] shares currently have an operating margin of -159.00 and a Gross Margin at +96.60. Karyopharm Therapeutics Inc.’s Net Margin is presently recorded at -181.59.
Return on Total Capital for KPTI is now -96.50, given the latest momentum, and Return on Invested Capital for the company is -111.33. Return on Equity for this stock declined to -391.29, with Return on Assets sitting at -64.56. When it comes to the capital structure of this company, Karyopharm Therapeutics Inc. [KPTI] has a Total Debt to Total Equity ratio set at 259.43. Additionally, KPTI Total Debt to Total Capital is recorded at 72.18, with Total Debt to Total Assets ending up at 41.89. Long-Term Debt to Equity for the company is recorded at 255.63, with the Long-Term Debt to Total Capital now at 71.12.
Reflecting on the efficiency of the workforce at the company, Karyopharm Therapeutics Inc. [KPTI] managed to generate an average of -$454,336 per employee. Receivables Turnover for the company is 10.42 with a Total Asset Turnover recorded at a value of 0.36.Karyopharm Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.10 and a Current Ratio set at 4.10.
Insider trade positions for Karyopharm Therapeutics Inc. [KPTI]
There are presently around $347 million, or 80.80% of KPTI stock, in the hands of institutional investors. The top three institutional holders of KPTI stocks are: BLACKROCK INC. with ownership of 7,749,757, which is approximately 3.674% of the company’s market cap and around 3.20% of the total institutional ownership; PALO ALTO INVESTORS LP, holding 5,363,652 shares of the stock with an approximate value of $31.81 million in KPTI stocks shares; and STATE STREET CORP, currently with $31.62 million in KPTI stock with ownership of nearly -0.142% of the company’s market capitalization.
Positions in Karyopharm Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 79 institutional holders increased their position in Karyopharm Therapeutics Inc. [NASDAQ:KPTI] by around 8,363,847 shares. Additionally, 90 investors decreased positions by around 11,800,607 shares, while 24 investors held positions by with 38,390,693 shares. The mentioned changes placed institutional holdings at 58,555,147 shares, according to the latest SEC report filing. KPTI stock had 26 new institutional investments in for a total of 1,869,735 shares, while 31 institutional investors sold positions of 2,807,535 shares during the same period.